Calcipotriol/Betamethasone Dipropionate Aerosol Foam for Plaque Psoriasis: A Prospective, Observational, Non-Interventional, Single-Center Study of Patient Adherence and Satisfaction in Daily Use
Metadatos
Mostrar el registro completo del ítemEditorial
Derm101
Materia
Adherence Satisfaction Calcipotriol/betamethasone Aerosol foam Psoriasis
Fecha
2021-05-20Referencia bibliográfica
Navarro-Triviño FJ, Lozano-Lozano M, Ruiz-Villaverde R. Calcipotriol/betamethasone aerosol foam for plaque psoriasis: a prospective, observational, non-interventional, single-center study on patient adherence and satisfaction in daily use. Dermatol Pract Concept. 2021;11(3):e2021056. DOI: [https://doi.org/10.5826/dpc.1103a56]
Patrocinador
LEO PharmaResumen
Background: Psoriasis is a chronic inflammatory disease that has a negative impact on patients’ quality
of life. Patients with mild–moderate psoriasis can be treated with topical medications, such as the
combination drug calcipotriol/betamethasone dipropionate (Cal/BD).
Objectives: This study investigated the adherence of psoriasis patients to therapy with Cal/BD aerosol
foam, as well as their satisfaction with the treatment’s efficacy, safety, and effect on their quality of life.
Methods: Patients with mild–moderate plaque psoriasis were eligible to participate in this open-label,
non-placebo controlled, prospective single-center study. Adherence to treatment was assessed using the
Morisky-Green scale 4 and 12 weeks after the start of treatment. Satisfaction with the treatment was
assessed using the abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9). The
severity of psoriasis was assessed on the mIGA and PGA scales, and the impact on quality of life was
assessed using the PDI and DLQI scales.
Results: A total of 65 patients entered the study. Adherence to treatment was good, with 73.8% of
patients showing high adherence at 12 weeks. Satisfaction was also good, with 46 patients (70.8%)
being completely satisfied. Conclusions: Over a 4-week period, patients treated with Cal/BD aerosol foam had significant improvement
in disease severity that was directly related to treatment adherence.